JP2021134211A - Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ - Google Patents

Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ Download PDF

Info

Publication number
JP2021134211A
JP2021134211A JP2021023812A JP2021023812A JP2021134211A JP 2021134211 A JP2021134211 A JP 2021134211A JP 2021023812 A JP2021023812 A JP 2021023812A JP 2021023812 A JP2021023812 A JP 2021023812A JP 2021134211 A JP2021134211 A JP 2021134211A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
indazole
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021023812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021134211A5 (https=
Inventor
バークリシャン エーミン ニータ
Balkrishan Amin Neeta
バークリシャン エーミン ニータ
ジェイムズ バーグマン アーサー
James Bergman Arthur
ジェイムズ バーグマン アーサー
アーノルド カル ロバート
Arnaldo Calle Roberto
アーノルド カル ロバート
ポール エズラー ウィリアム
Paul Esler William
ポール エズラー ウィリアム
ミュン キム アルバート
Myung Kim Albert
ミュン キム アルバート
アレン フェファーコーン ジェフリー
Allen Pfefferkorn Jeffrey
アレン フェファーコーン ジェフリー
ロバート ヴァーホスト パトリック
Robert Verhoest Patrick
ロバート ヴァーホスト パトリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of JP2021134211A publication Critical patent/JP2021134211A/ja
Publication of JP2021134211A5 publication Critical patent/JP2021134211A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021023812A 2020-02-24 2021-02-18 Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ Pending JP2021134211A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062980664P 2020-02-24 2020-02-24
US62/980664 2020-02-24

Publications (2)

Publication Number Publication Date
JP2021134211A true JP2021134211A (ja) 2021-09-13
JP2021134211A5 JP2021134211A5 (https=) 2024-01-24

Family

ID=74844948

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021023812A Pending JP2021134211A (ja) 2020-02-24 2021-02-18 Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ

Country Status (7)

Country Link
US (1) US12472180B2 (https=)
EP (1) EP4110395A1 (https=)
JP (1) JP2021134211A (https=)
AR (1) AR121400A1 (https=)
CA (1) CA3172765A1 (https=)
TW (1) TW202140004A (https=)
WO (1) WO2021171164A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119219759B (zh) * 2024-10-22 2026-03-27 浙江工业大学 一种双水相萃取耦合反相柱层析分离纯化发酵液中glp-1类似物的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013540119A (ja) * 2010-09-30 2013-10-31 ファイザー・インク Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害剤
WO2018033832A1 (en) * 2016-08-19 2018-02-22 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
JP2018501276A (ja) 2015-01-09 2018-01-18 ギリアド アポロ， エルエルシー 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
SI3397631T1 (sl) 2015-12-29 2022-01-31 Pfizer Inc. Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze
EP3555064B9 (en) 2016-12-16 2023-03-01 Pfizer Inc. Glp-1 receptor agonists and uses thereof
FI3713942T3 (fi) 2017-11-21 2023-05-04 Pfizer 4-(4-(1-isopropyyli-7-okso-1,4,6,7-tetrahydrospiro[indatsoli-5,4'-piperidiini]-1'-karbonyyli)-6-metoksipyridin-2-yyli)bentsoehapon kiteinen 2-amino-2-(hydroksimetyyli)propaani-1,3-diolisuola
CR20210110A (es) * 2018-08-31 2021-05-13 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas
WO2020234726A1 (en) * 2019-05-20 2020-11-26 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013540119A (ja) * 2010-09-30 2013-10-31 ファイザー・インク Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害剤
WO2018033832A1 (en) * 2016-08-19 2018-02-22 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors

Also Published As

Publication number Publication date
US12472180B2 (en) 2025-11-18
US20230218616A1 (en) 2023-07-13
WO2021171164A1 (en) 2021-09-02
CA3172765A1 (en) 2021-09-02
EP4110395A1 (en) 2023-01-04
TW202140004A (zh) 2021-11-01
AR121400A1 (es) 2022-06-01

Similar Documents

Publication Publication Date Title
TWI718644B (zh) 用於治療ｎａｓｈ／ｎａｆｌｄ和相關疾病之組合
US11866425B2 (en) Diacylglycerol acyl transferase 2 inhibitors
JP2020200308A (ja) Ｎａｓｈ／ｎａｆｌｄおよび関連疾患治療のための組合せ
TWI771766B (zh) 二醯基甘油醯基轉移酶２ 抑制劑
UA128160C2 (uk) Сполуки, що інгібують rip1, а також способи їх одержання та застосування
US12472180B2 (en) Combinations for treatment of NAFLD/NASH and related diseases
JP2022058085A (ja) ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
RU2776369C1 (ru) Комбинации для лечения насг/нажбп и связанных с ними заболеваний
HK40055015A (en) Combinations for treatment of nash/nafld and related diseases
EA045908B1 (ru) Комбинации для лечения nash/nafld и родственных заболеваний
WO2019246427A1 (en) Crystalline forms of pyridinone-containing tricyclic compounds and methods of preparing and using same
BR112019001976B1 (pt) Inibidores da diacilglicerol aciltransferase 2, composições que os compreendem e usos dos mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250610